Companies › InxMed (Shanghai)
4 active drug programs in 16 registered trials: 10 Phase 1, 4 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ifebemtinib (IN10018) Focal adhesion kinase 1 inhibitor | PTK2 | Phase 3 | Non-Small Cell Lung Cancer; Ovarian Cancer Recurrent; Small Cell Lung Cancer Extensive Stage; Pancreatic Cancer … | Dec 2026 |
| D-1553 KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Solid Tumor | Dec 2027 |
| RNK08954 unclear mechanism | – | Phase 1 | Solid Tumor Cancer | Feb 2031 |
| Erfonrilimab (KN046) Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor | CTLA4, CD274 | Phase 1 | Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06030258 | Ifebemtinib (IN10018) | Phase 1 | Small Cell Lung Cancer Extensive Stage | Oncology | Dec 2025 |
| NCT05827796 | Ifebemtinib (IN10018) | Phase 1 | Pancreatic Cancer | Oncology | Dec 2025 |
| NCT05827796 | Erfonrilimab (KN046) | Phase 1 | Pancreatic Cancer | Oncology | Dec 2025 |
| NCT06654011 | Ifebemtinib (IN10018) | Phase 2 | Cervical Adenocarcinoma | Oncology | May 2026 |
| NCT05551507 | Ifebemtinib (IN10018) | Phase 1 | Platinum-resistant Ovarian Cancer | Oncology | May 2026 |
| NCT05994131 | Ifebemtinib (IN10018) | Phase 1 | NSCLC | Oncology | Jul 2026 |
| NCT06014528 | Ifebemtinib (IN10018) | Phase 2 | Ovarian Cancer Recurrent | Oncology | Dec 2026 |
| NCT06099821 | Erfonrilimab (KN046) | Phase 2 | Digestive System Cancers | Oncology | Dec 2026 |
| NCT06023758 | Erfonrilimab (KN046) | Phase 2 | HER2-positive Locally Advanced Resectable Gastric Cancer | Oncology | Dec 2026 |
| NCT06166836 | Ifebemtinib (IN10018) | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT06166836 | D-1553 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT07652762 | Ifebemtinib (IN10018) | Phase 1 | Meningioma | Oncology | Aug 2028 |
| NCT07174908 | Ifebemtinib (IN10018) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Sep 2028 |
| NCT07174908 | D-1553 | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Sep 2028 |
| NCT07441174 | Ifebemtinib (IN10018) | Phase 1 | Solid Tumor Cancer | Oncology | Feb 2031 |
| NCT07441174 | RNK08954 | Phase 1 | Solid Tumor Cancer | Oncology | Feb 2031 |
Genfleet Therapeutics (Shanghai) Verastem Day One Biopharmaceuticals Clarity Pharmaceuticals TYK Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.